Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
BioCentury | Feb 21, 2018
Distillery Therapeutics

Cancer

BioCentury | Jan 31, 2018
Distillery Therapeutics

Cancer

BioCentury | Aug 22, 2017
Distillery Therapeutics

Cancer

BioCentury | Aug 11, 2017
Tools & Techniques

K follows C in chemoproteomics

Chemoproteomic mapping of druggable lysines in the proteome
BioCentury | Nov 11, 2016
Tools & Techniques

Chemistry beyond candidates

AZN chemists tackle common problems in compound innovation
BioCentury | Nov 4, 2013
Finance

Calithera metabolizes

Calithera's second act as cancer metabolism play attracts $35M
BioCentury | Nov 11, 2010
Distillery Therapeutics

Indication: Cancer

BioCentury | Aug 30, 2010
Company News

Aileron, Roche deal

BioCentury | Aug 30, 2010
Product Development

Roche Goes Shopping for Staples

Roche increases commitment to Stapled Peptides technology at Aileron Therapeutics
Items per page:
1 - 10 of 33